The U.S. Agency for drug control (FDA) approved the marketing of Yervoy (Ipilimumab) Bristol-Myers Squibb, the first life-prolonging treatment of patients with advanced melanoma according to a statement released Friday.
"Yervoy is the first therapy approved by the FDA clearly showed extending the life of patients suffering from metastatic melanoma, "said Richard Pazdur, director of the office assessment of the FDA anti-cancer treatments.
melanoma, skin cancer, is a of the deadliest forms of cancer. Its incidence has increased among all forms of tumor in the last thirty years.
The phase 3 clinical study of 649 patients in several countries, showed that those treated with Yervoy, survived ten months after diagnosis, six months against ½ surviving patients who received an experimental anti-cancer vaccine, ie a life expectancy of over 50%.
The Ipilimumab is a monoclonal antibody administered intravenously, generally well tolerated. Unlike most treatments for cancer cells, this antibody belongs to a new class of drugs that activate T cells (lymphocytes), a class of lymphocytes that play a key role in the cellular immune response.
According to WHO, skin cancer responsible for 66,000 deaths per year worldwide, 80% due to melanomas. More than half of patients are younger than 59 years.
were diagnosed in the United States 68,130 new cases of melanoma in 2010 and killed 8,700 people, according to the U.S. National Cancer Institute.
| Ipilimumab | |
| Monoclonal antibody | |
| Whole antibody | |
| Identifiers | |
| None | |
| Chemical data | |
| 148634.914 g/mol | |
| Therapeutic considerations | |
| ? | |
| ? | |
| | |
0 comments:
Post a Comment